The PROMINENT trial, published in 2022, tested pemafibrate, a novel selective PPAR-α modulator, in over 10,000 statin-treated patients with type 2 diabetes and mild to moderate HTG (median TG 271 mg/dL). Here, PPARA is linked to type 2 diabetes mellitus.